PMD Device Solutions (“PMD”) has consolidated the US acquisition and a combination of cost control and organic growth allows PMD to aim for a cash-positive run-rate before the end of 2024 whilst setting an target to reach SEK 260m in ARR by 2026. The near term challenge is to extend the growth rate and to manage limited access to growth capital.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/